1 research outputs found
Mepolizumab does not alter the blood basophil count in severe asthma.
[First paragraph] To the Editor:
Mepolizumab (antiâILâ5) depletes blood and airway eosinophils, and, clinically, allows downâtitration of oral corticosteroid and a reduction in the frequency of eosinophilâdependent exacerbations.1 Basophils also express ILâ5Rα, participate in T2âmediated inflammatory pathways2 and have been associated with exacerbation frequency.3 Whilst basophil progenitors are unlikely to depend on ILâ5 for development,4 blood basophil counts measured in routine clinical laboratories suggest they decrease following mepolizumab treatment.5-